arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Equillium, Inc.

EQ
$1.34 ▼ -0.04 (-3.25%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
37 Visible periods
30 Metrics
Peer-ranked Benchmarks
Price Chart
27
Health
Poor
Bearish
auto_awesome

Analytical Summary

Equillium, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $149.8M
Dividend Yield —
Revenue Growth None
Op. Margin None
ROIC -7.3% ↗
FCF / Share $-0.04 ↗
Trailing P/E —
Price / Book 1.5x
FCF Yield —
Debt / Equity —
info Valuation on last close. End-of-day price, Nov 5, 2026.

37-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$4.39M
↓ -52.3% —
Net Income Profit after all expenses
$-5.31M
↑ +38.6% —
Operating Margin Operating profit as % of sales
-107.0%
↓ -1815.8% —
FCF / Share Free cash flow per share
$-0.04
↑ +16.4% —
Long-Term Debt Long-term obligations
$7.64M
↓ -26.0% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns ↓
11
Cash Quality ↑
66

bar_chart Data from SEC EDGAR XBRL filings

Synced 5 days ago 10 years · 37 quarters